Yang Qing-Ming - Department of Molecule and Immunology, Chinese PLA General Hospital

基本信息

浏览量：8

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 42 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Epigenetic Agents Plus Anti-Pd-1 Reprogram the Tumor Microenvironment and Restore Antitumor Efficacy in Hodgkin Lymphoma

Jing Nie,Chunmeng Wang,Liangtao Zheng,Yang Liu, Chengcheng Wang, Yixin Chang, Yudi Hu, Bing Guo,Yuting Pan,Qingming Yang,Xueda Hu,Weidong Han

BLOOD（2024）

引用0浏览0WOS引用

Inhibition of Glycosphingolipid Synthesis with Eliglustat in Combination with Immune Checkpoint Inhibitors in Advanced Cancers: Preclinical Evidence and Phase I Clinical Trial

Liang Dong, Zhi Cao,Meixia Chen,Yang Liu, Xinran Ma,Yuting Lu,Yan Zhang,Kaichao Feng, Yang Zhang,Zhenzhen Meng,Qingming Yang,Yao Wang,Zhiqiang Wu,Weidong Han

Nature Communicationsno. 1 (2024)

引用1浏览0WOSNATURE引用

Manganese primed immunochemotherapy in platinum-resistant/refractory ovarian cancer: a randomized, single-blind, placebo-controlled, phase 2 trial

Weidong Han,Qian Mei,Yan Zhang,Jiejie Liu,Meixia Chen, Yandong Gong,Yang Liu, Tiance Wang,Mingxia Ye,Zhengfan Jiang, Qianyi Ming, Zijian Lv,Runjia Fan,Qingming Yang, Yuan Du,Yuanguang Meng

crossref（2024）

引用0浏览0引用

PRELIMINARY DATA FROM A FIRST‐IN HUMAN PHASE II STUDY OF SEQUENTIAL USE OF SELINEXOR AND CD19 CART THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA

Y. Zhang,X. Zong,S. Jia,J. Li,H. Geng, L. Zeng,Q. Yang, W. Cai, S. Liu, Y. Lu,L. Yu,C. Li,D. Wu

Hematological Oncologyno. S2 (2023): 784-785

引用0浏览0引用

Supplementary Appendix from Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: an Open-Label Phase I Trial

Chun-Meng Wang,Zhi-Qiang Wu,Yao Wang,Ye-Lei Guo,Han-Ren Dai, Xiao-Hui Wang,Xiang Li,Ya-Jing Zhang,Wen-Ying Zhang,Mei-Xia Chen,Yan Zhang,Kai-Chao Feng,Yang Liu,Su-Xia Li,Qing-Ming Yang,Wei-Dong Han

openalex（2023）

引用0浏览0引用

Supplementary Fig 5 from Efficacy of Decitabine Plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy

Chunmeng Wang,Yang Liu, Liang Dong,Xiang Li,Qingming Yang,Malcolm V. Brock,Qian Mei, Jiejie Liu,Meixia Chen, Fengxia Shi,Miao Liu,Jing Nie,Weidong Han

openalex（2023）

引用0浏览0引用

Long‐term Complete Remission and Peripheral Biomarkers in Hodgkin Lymphoma Patients after Decitabine‐plus‐camrelizumab Epi‐immunotherapy and Treatment Cessation

Chunmeng Wang,Yuting Pan,Yang Liu, Bing Guo, Jinhong Shi,Guanghua Rong, Zhipeng Guo, Zhifang Li,Qingming Yang,Jing Nie,Weidong Han

MedCommno. 6 (2023)

引用1浏览0WOS引用

Supplementary Figure 2 from Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: an Open-Label Phase I Trial

Chun-Meng Wang,Zhi-Qiang Wu,Yao Wang,Ye-Lei Guo,Han-Ren Dai,Xiao-Hui Wang,Xiang Li,Ya-Jing Zhang,Wen-Ying Zhang,Mei-Xia Chen,Yan Zhang,Kai-Chao Feng,Yang Liu,Su-Xia Li,Qing-Ming Yang,Wei-Dong Han

openalex（2023）

引用0浏览0引用

Characteristics of Premanufacture CD8+T Cells Determine CAR-T Efficacy in Patients with Diffuse Large B-cell Lymphoma

Yao Wang,Chuan Tong,Yuting Lu,Zhiqiang Wu,Yelei Guo,Yang Liu,Jianshu Wei,Chunmeng Wang,Qingming Yang,Weidong Han

SIGNAL TRANSDUCTION AND TARGETED THERAPY（2023）

引用10浏览0WOSNATURE引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn